Quick Answer
Harmony Biosciences Holdings, Inc. reported Gross Profit of $670.11 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +20.1% in Gross Profit from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $16.37 million | Q2 2020: $31.55 million | Q3 2020: $37.72 million | Q1 2021: $49.27 million | Q2 2021: $61.13 million | Q3 2021: $66.13 million | Q1 2022: $70.60 million | Q2 2022: $88.11 million | Q3 2022: $94.25 million | Q1 2023: $98.35 million | Q2 2023: $109.21 million | Q3 2023: $127.97 million | Q1 2024: $127.13 million | Q2 2024: $140.67 million | Q3 2024: $143.26 million | Q1 2025: $152.74 million | Q2 2025: $162.34 million | Q3 2025: $179.81 million.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Gross Profit has grown by 15,067.7%.
- Historical annual values: Fiscal year 2025: $670.11 million | Fiscal year 2024: $557.92 million | Fiscal year 2023: $460.79 million | Fiscal year 2022: $354.37 million | Fiscal year 2021: $249.92 million | Fiscal year 2020: $132.00 million | Fiscal year 2019: $4.42 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: